

---

HTA - - Health Technology Assessment Report

## **Tobramycin inhalation powder versus Tobramycin inhalation solution for cystic fibrosis (Structured abstract)**

**Code:** HTA-32016000894 **Year:** 2015 **Date:** 2015

**Author:** Hernández-Vásquez A

### **Interventions**

Tobramycin inhalation powder versus Tobramycin inhalation solution

### **Main results**

There is moderate quality evidence, including a single study comparing both inhalation modes. No significant differences were found in clinically significant results between tobramycin inhalation solution and tobramycin inhalation powder.

### **Authors' conclusions**

The clinical practice guidelines and coverage policies found do not consider tobramycin inhalation powder as a first line treatment and in some cases, they mention it as a treatment alternative only under certain conditions such as intolerance or no response to colistin solution, colistin powder or tobramycin inhalation solution; and with price reduction agreements that make tobramycin inhalation power more affordable.

<http://onlinelibrary.wiley.com/o/cochrane/clhta/articles/HTA-32016000894/frame.html>

### **See also**

Health Technology Assessment Database- Institute for Clinical Effectiveness and Health Policy (IECS)

### **Keywords**

Anti-Bacterial Agents; Bacterial Infections; Infection; Inhalation OR nebulised; pharmacological\_intervention; Powders; Pseudomonas aeruginosa; Pseudomonas; Respiratory Tract Diseases; Respiratory Tract Infections; Tobramycin; Aminoglycosides;